Filing Flows › Companies › Evolent Health › Timeline
Evolent Health stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−23.7% to $4.58
Evolent Health (EVH) stock fell 24% over the last 252 sessions, to $4.58. On the way it reported 5 quarters, its insiders filed 1 open-market trade and 1 Form 144 notice of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: missed the EPS estimate by 0.0% | −5.6% (−1.1% vs SPY) | — | — |
| Aug 26, 2026 | Form 144 | Form 144: Daniel McCarthy plans to sell $327K | +0.6% (+0.6% vs SPY) | −13.3% (−12.8% vs SPY) | −32.9% (−33.3% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 229.9% | +15.3% (+15.5% vs SPY) | +30.3% (+29.9% vs SPY) | +32.4% (+32.0% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 57.2% | +10.9% (+11.2% vs SPY) | +7.5% (+6.4% vs SPY) | +9.7% (+9.2% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: beat the EPS estimate by 62.7% | −7.9% (−8.6% vs SPY) | +25.6% (+25.1% vs SPY) | −20.8% (−16.7% vs SPY) |
| Dec 2, 2025 | 8-K | Directors and officers: departures, appointments, pay | −3.0% (−3.2% vs SPY) | −1.8% (−2.3% vs SPY) | 0.0% (−0.5% vs SPY) |
| Nov 18, 2025 | Insider buy | Springstubb Brendan B bought $38K | +3.3% (+4.1% vs SPY) | +9.8% (+9.4% vs SPY) | +4.3% (+3.4% vs SPY) |
| Nov 6, 2025 | 8-K | Directors and officers: departures, appointments, pay | −19.0% (−19.1% vs SPY) | −36.6% (−36.9% vs SPY) | −42.3% (−44.3% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: missed the EPS estimate by -51.2% | −5.7% (−4.6% vs SPY) | −35.6% (−36.4% vs SPY) | −47.7% (−48.9% vs SPY) |
Insiders’ record here
In the year on the chart, Evolent Health's insiders reported 1 open-market buy ($38K) and 0 sales ($0). Of the 1 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was −34.7% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Evolent Health: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.